99

Intestinal failure-associated liver disease (IFALD) refers to all liver damages occurring in patients with chronic intestinal failure and resulting from one or more factors, with parenteral nutrition representing the cornerstone of their management. Although poorly codified, IFALD is the most frequent and lethal complication of chronic intestinal failure, with a mortality rate of up to 22% in adults and 40% in children. No drug strategy is currently recommended for the treatment of IFALD. This is why its management relies primarily on reinforcing preventive measures, such as preventing episodes of sepsis, maintaining oral intake, adapting parenteral nutrition, and preserving intestinal length. In recent years, a number of non-invasive screening strategies have been developed, notably elastography, but their place in the management of IFALD remains to be defined, and further studies are needed to validate their use.